Trial reportClinical ophthalmology (Auckland, N.Z.)2026
12-Month Visual and Clinical Outcomes After Implantation of a Monofocal Aspheric Hydrophobic Acrylic IOL: A Prospective Feasibility Study.
Trial report in Clinical ophthalmology (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate 12-month visual and clinical outcomes after implantation of a monofocal aspheric hydrophobic acrylic intraocular lens (IOL) delivered with a preloaded system. Methods: This investigator-initiated, prospective, single-center, uncontrolled feasibility study enrolled 30 patients undergoing unilateral or bilateral cataract surgery with implantation of the OPTIFLEX GENESIS COMFORT NY IOL. Twenty patients contributed 22 operative eyes to the per-treatment evaluable analysis at 12 months. Uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), manifest refraction, contrast sensitivity, and intraocular pressure (IOP) were assessed postoperatively. Posterior capsule opacification (PCO), clinically detectable IOL tilt, decentration, discoloration, and higher-order aberrations were evaluated during follow-up. Results: Mean preoperative UDVA and CDVA were 0.64 ± 0.33 and 0.30 ± 0.23 logMAR, respectively. Mean UDVA improved to 0.12 ± 0.16 logMAR at 3 months and 0.19 ± 0.16 logMAR at 12 months. Mean CDVA improved to -0.01 ± 0.10 logMAR at 3 months and 0.01 ± 0.09 logMAR at 12 months. IOP remained stable, and no statistically significant change in spherical equivalent refraction was observed, although a numerical hyperopic trend was noted. At 12 months, PCO was absent in 15 eyes and minimal in 7 eyes. No clinically detectable IOL tilt, decentration, or discoloration was recorded. Contrast sensitivity was generally within or close to age-matched reference ranges. Conclusion: In this uncontrolled prospective feasibility cohort, implantation of the investigated monofocal aspheric hydrophobic acrylic IOL was associated with improved distance visual acuity and stable IOP through 12 months. The findings provide preliminary device-specific clinical data and should be confirmed in larger controlled studies with longer follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.